[Cryoimmunological therapy with local injection of OK-432 against advance or recurrent breast cancer].
A total of 5 breast cancer patients, 2 with far advanced primary breast tumor and 3 with local recurrent tumors on their anterior chest wall, underwent multimodal therapy in which cryosurgery was performed in combination with local injection of the non-specific immunopotentiator OK-432. This multimodal therapy was repeated as many times as possible. In addition, all patients were treated with mild chemotherapy. In every patient who underwent cryosurgery combined with locoregional immunotherapy, eradication or reduction of tumor was observed for several months. In 3 of the patients who underwent cryosurgery, locoregional immunotherapy and systemic chemotherapy, the tumor burden decreased markedly in 2 patients even though the diameter of tumor was over 5 cm in both cases. In case 1, we examined the concentration of IFN-gamma and IL-10 before and after cryosurgery. The value of IFN-gamma/IL-10 increased from 3.0 to 6.1 after treatment. All patients experienced high fever within 2 days after surgery, but no other side effects resulted from either cryosurgery or locoregional immunotherapy. All patients maintained good QOL throughout their therapy. These results indicate that cryosurgery in combination with local injection of OK-432 should be a feasible modality against unresectable breast cancer on the chest wall, and that this therapeutic effect may be augmented by mild chemotherapy.
Kawaguchi
Yoshihiro
Y
Dept. of Tumor and General Surgery, Gifu University School of Medicine.
Sugiyama
Yasuyuki
Y
Saji
Shigetoyo
S
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003452:Cryosurgery; D000077143:Docetaxel; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D015552:Injections, Intralesional; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage; D010844:Picibanil / Q000008:administration & dosage*; D043823:Taxoids / Q000008:administration & dosage
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D010844:Picibanil; D015251:Epirubicin; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil